You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The funding will allow the company to accelerate development of its DNA synthesis technology, hire staff, build an R&D facility, and establish industrial partnerships.
The companies, which have been working since early 2019, will work together on Evonetix's first product, a desktop DNA synthesizer.
Horizons Ventures led the round, joined by Airbus Ventures, bringing the MIT spinout's fundraising total to date to more than $21 million.
BGI will have a chance to depose up to nine inventors of patents assigned to Illumina as part of a lawsuit over IP related to sequencing-by-synthesis chemistry.
The Bay Area DNA synthesis company said it was "not significantly affected" by the COVID-19 pandemic and beat Wall Street revenue estimates.
The firm added $50 million from Casdin Capital, Danaher Life Sciences, and Agilent Technologies to its $38.5M Series B round announced in May 2019.
The North Carolina State University team is working on scaling the technology further and may form a company to develop it commercially.
Molecular Assemblies will combine its chemistries with Codexis' enzyme improvement platform in order to create a process for the enzymatic synthesis of DNA.
The firm is offering approximately 3 million shares and said it may use a portion of the proceeds to acquire, license, or invest in complementary businesses or products.
Single-cell analysis, next-generation sequencing, and synthetic DNA have all been crucial to efforts to find antibodies that could neutralize SARS-CoV-2.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.